Maggie Wong is a partner in Goodwin’s nationally recognized Life Sciences group. She represents private and public companies in the biotechnology, medical device and digital health industries, serving as a legal and business adviser across their entire corporate lifecycle. Ms. Wong provides strategic advice and corporate counseling to clients as they develop, in-license and acquire intellectual property and other assets, raise capital to fund their operations and seek to partner their technology or engage in exit transactions. Ms. Wong regularly counsels clients on pre-incorporation planning, seed and venture financings, initial public offerings and capital markets transactions, SEC compliance, and mergers and acquisitions. She also has substantial experience advising on licensing, collaboration, partnering, distribution and other commercial agreements.

Ms. Wong is also a member of Goodwin’s PropSci practice which is focused on supporting the intersection of real estate and life sciences through thoughtful collaboration across the two practice areas. As a key contributor to the group and Steering Committee, Ms. Wong stays up to date on relevant market trends impacting the PropSci sector to effectively support clients involved in this space.





Private Company Financing Transactions

  • Alector Corporation in its $133 million Series E Preferred Stock financing
  • BridgeBio Pharma in its $299.2 million Series D financing
  • BridgeBio Pharma in its $65 million initial investment in and launch of QED Therapeutics
  • Delinia in its $35 million Series A Preferred Stock financing
  • Eidos Therapeutics in its $64 million Series B Preferred Stock financing
  • Global Blood Therapeutics in its $40.7 million Series A Preferred Stock financing and $48 million Series B Preferred Stock financing
  • MyoKardia in its $46 million Series B Preferred Stock financing
  • Spinifex Pharmaceuticals in its $45 million Series C Preferred Stock financing

Initial Public Offerings and Public Company Financing Transactions

  • BridgeBio Pharma in its $372 million initial public offering and $475 million convertible senior note offering
  • Eidos Therapeutics in its $122 million initial public offering
  • Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million, $125 million, $100 million and $250 million follow-on public offerings
  • MyoKardia in its $54 million initial public offering and subsequent $65 million, $134 million, $184 million, $271 million and $604 million follow-on public offerings
  • Assembly Biosciences in its $60 million and $155 million follow-on public offerings and establishment of a $75 million “at the market” offering facility
  • aTyr Pharma in its $75 million initial public offering
  • Fate Therapeutics, Inc. in its initial public offering, subsequent follow-on public offerings and private placement transactions

M&A and Other Strategic Transactions

  • Delinia in its sale to Celgene for $300 million upfront and $475 million in milestone payments
  • F-star Alpha in its exclusive option agreement with Bristol-Myers Squibb for aggregate consideration of up to $475 million
  • Spinifex Pharmaceuticals in its $200 million upfront sale to Novartis plus undisclosed clinical development and regulatory milestones
  • BridgeBio Pharma in its agreement with Alexion Pharmaceuticals to acquire a synthetic enzyme co-factor therapy and its launch of Origin Biosciences to support the compound’s clinical development
  • Artisan Pharma in its sale to Asahi Kasei Pharma for an undisclosed amount
  • Assembly Pharmaceuticals in its merger with Ventrus Biosciences to become Assembly Biosciences, Inc. (NASDAQ: ASMB)
  • Gallus Biopharmaceuticals in its acquisition from Centocor Biologics, a subsidiary of Johnson & Johnson, of an FDA-approved, commercially certified biologics manufacturing facility and its entry into an agreement for the commercial manufacture of Remicade and Stelara
  • Alere in its acquisition from ACON Laboratories of ACON’s worldwide lateral flow immunoassay diagnostics business
  • A major buyer of pharmaceutical royalties in the acquisition of a royalty interest from a private university for over $90 million
Professional Activities

Ms. Wong is a member of the American Bar Association and the San Francisco Bar Association.

Professional Experience

Prior to joining Goodwin, Ms. Wong was a corporate associate at Cooley LLP and Heller Ehrman LLP representing emerging companies. During law school, Ms. Wong interned in the Office of the General Counsel of the U.S. Securities and Exchange Commission in Washington, D.C.


Ms. Wong has been recognized by The Legal 500 U.S. and LMG Life Sciences for her corporate and transactional work in the life science industry. In law school, Ms. Wong was a Senior Articles Editor for the Asian Law Journal.

In The News









University of California, Berkeley, School of Law

(Order of the Coif)

Yale University

(cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique